LSTA — LISATA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 320017 ·
Last close
$1.04
Market Cap
$11.24M
52W High
$5.07
52W Low
$0.96
ADV30
139,040
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -10,030,000 | -6,787,000 | 648,410,000 | 282,717,000 | 640,767,000 |
| Jun 2026 | 0 | — | -3,992,000 | -2,929,000 | 11,027,000 | 10,443,000 | 3,037,000 |
| Mar 2026 | 0 | — | -4,942,000 | -4,489,000 | 14,059,000 | 13,060,000 | 3,387,000 |
| Dec 2025 | 100,000 | — | -3,079,000 | -2,954,000 | 17,744,000 | 15,956,000 | 3,143,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,323,000
Investing CF
$5,150,000
Financing CF
$768,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.85
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-572,070,000
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-16,427,000
Pretax Income TTM
$-15,008,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$100,000
EBITDA
$-16,362,000
Free Cash Flow
$-8,100,250
Enterprise Value
$206,233
Total Cash
$10,443,000
Total Debt
$0
Shares Out
10,804,066
Trailing EPS
$-1.64
Book Value
$1.68
ROE
-101.7%
ROA
-56.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,000 | -18,209,000 | -16,586,000 | 17,744,000 | 3,143,000 | 14,855,000 | -15,949,000 |
| Dec 2024 | 1,000,000 | -22,409,000 | -19,985,000 | 35,002,000 | 5,685,000 | 29,571,000 | -19,356,000 |
| Dec 2023 | 0 | -25,708,000 | -20,840,000 | 54,694,000 | 6,800,000 | 48,148,000 | -20,032,000 |
| Dec 2022 | 0 | -57,601,000 | -54,225,000 | 73,034,000 | 6,710,000 | 66,578,000 | -21,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$100,000
NetIncome TTM
$-14,621,000
OpCashFlow TTM
—
Assets (Latest)
$11,027,000
Forward EPS
$-1.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASBP | Aspire-Lakewood Holdings, Inc. | $11.64M | $8.30 | — |
| HIND | Vyome Holdings, Inc | $10.84M | $1.54 | — |
| CMMB | Chemomab Therapeutics Ltd. | $12.02M | $1.64 | — |
| OPTH | Optimi Health Corp. | $12.02M | $2.10 | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $10.38M | $0.12 | — |
News headlines (Yahoo Finance, 1h cache)
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-B
2026-11-09 14:00 · Yahoo
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
2026-11-05 13:30 · Yahoo
Lisata adds biopharma finance veteran Jeffrey Farrow to board
2026-10-15 12:41 · Yahoo
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
2026-10-14 20:05 · Yahoo
Lisata Therapeutics wins new US patent for pancreatic cancer drug
2026-10-08 13:10 · Yahoo
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
2026-10-08 12:00 · Yahoo
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
2026-10-05 13:43 · Yahoo
MARKETS LIVE: Nasdaq hits record high as tech stocks lead Wall Street higher
2026-10-05 11:03 · Yahoo
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
2026-09-24 12:55 · Yahoo
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
2026-09-24 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.